Tralokinumab Real-World Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis Adult Patients in the United States: 6-Month Interim Analysis. (2024). SKIN The Journal of Cutaneous Medicine, 8(1), s318. https://doi.org/10.25251/skin.8.supp.318